← Metformin × adverse events & safety

SynthesisJournal of diabetes research2019

Monotherapy with Metformin versus Sulfonylureas and Risk of Cancer in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis.

Abraham Nigussie Mekuria et al.PubMed ↗Full text ↗Publisher ↗

What the trial testedas reported · 2019

Not counted

Probably lowered adverse events & safety

−26%−45% to −1%

Bigger than 6 in 10 for adverse events & safety

As reported

RR 0.74, 95% CI 0.55–0.99

What moved togetherboth groups pooled, not the treatment’s effect

Correlation, not cause

Went with lower adverse events & safety

−26%−45% to −1%

Bigger than 6 in 10 for adverse events & safety

As reported

RR 0.74, 95% CI 0.55–0.99

Correlation · may be no link

No clear link with adverse events & safety

−24%−46% to +7%

Bigger than 6 in 10 for adverse events & safety

As reported

RR 0.76, 95% CI 0.54–1.07

Three numbers in the abstract

the abstract, start to end

… of cancer incidence (unadjusted RR = 0.74, 95% CI: 0.55-0.99, …

… than SUs in T2DM patients (RR = 0.76, 95% CI: 0.54-1.07, I 2 = …

… using SUs as a monotherapy (RR = 0.74, 95% CI: 0.55-0.99, I 2 = …

← favours treatmentfavours comparator →
could be chance
Adverse events & safety
RR 0.740.55–0.99
Adverse events & safety
RR 0.760.54–1.07
Adverse events & safety
RR 0.740.55–0.99
MetforminSulfonylureas & glinidesAdverse events & safety
1 / 3

19 papers cite it

2019
2020
2021
2022
2023
2024
2025
this paperpooled ittrialcites it
Full record →Abstract, authors, funding and every citing paper · PMID 31828167